In the present study, we examined the consequence of FOXO1 expression correlating with paclitaxel cytotoxicity and sensitivity in ovarian cancer cell lines using parent cells and paclitaxel-resistant derivative cells, and confirmed its expression in clinical samples from chemosensitive and resistant patients. The gene discussed is FOXO1; the disease is ovarian carcinoma.